New Delhi, February 19 Dr. Reddy's Laboratories has entered the hormone replacement therapy segment by acquiring the trademarks of specialty brands, Progynova and Cyclo-Progynova, and related assets for India from UK-based Mercury Pharma Group for USD 32.15 million, according to a company statement.
Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of symptoms of estrogen deficiency and for the prevention of postmenopausal osteoporosis.
Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of symptoms of estrogen deficiency, providing both estrogen and progestogen components.
According to IQVIA MAT December 2025, the brand recorded sales of INR 100 crore.
The acquisition strengthens Dr. Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated.
"This acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India. With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact," said Dr. Reddy's Laboratories CEO, Branded Markets (India and Emerging Markets), MV Ramana.
Dr. Reddy's shares on Wednesday ended 0.32 per cent down at INR 1,280.85 apiece on BSE.